- Home
- MOLN vs NKTR Comparison
MOLN vs NKTR Comparison
Compare MOLN & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- NKTR
- Stock Information
- Founded
- MOLN 2004
- NKTR 1990
- Country
- MOLN Switzerland
- NKTR United States
- Employees
- MOLN N/A
- NKTR N/A
- Industry
- MOLN
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- NKTR Health Care
- Exchange
- MOLN Nasdaq
- NKTR Nasdaq
- Market Cap
- MOLN 136.1M
- NKTR 108.3M
- IPO Year
- MOLN 2021
- NKTR 1994
- Fundamental
- Price
- MOLN $3.71
- NKTR $24.31
- Analyst Decision
- MOLN
- NKTR Strong Buy
- Analyst Count
- MOLN 0
- NKTR 6
- Target Price
- MOLN N/A
- NKTR $77.50
- AVG Volume (30 Days)
- MOLN 2.4K
- NKTR 4.4M
- Earning Date
- MOLN 08-25-2025
- NKTR 08-07-2025
- Dividend Yield
- MOLN N/A
- NKTR N/A
- EPS Growth
- MOLN N/A
- NKTR N/A
- EPS
- MOLN N/A
- NKTR N/A
- Revenue
- MOLN $2,525,030.00
- NKTR $87,248,000.00
- Revenue This Year
- MOLN N/A
- NKTR N/A
- Revenue Next Year
- MOLN $866.67
- NKTR N/A
- P/E Ratio
- MOLN N/A
- NKTR N/A
- Revenue Growth
- MOLN N/A
- NKTR N/A
- 52 Week Low
- MOLN $3.36
- NKTR $6.48
- 52 Week High
- MOLN $12.22
- NKTR $37.38
- Technical
- Relative Strength Index (RSI)
- MOLN 51.23
- NKTR 68.55
- Support Level
- MOLN $3.58
- NKTR $8.27
- Resistance Level
- MOLN $3.86
- NKTR $37.38
- Average True Range (ATR)
- MOLN 0.16
- NKTR 3.54
- MACD
- MOLN 0.01
- NKTR 1.72
- Stochastic Oscillator
- MOLN 50.79
- NKTR 55.75
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.